Novartis Can’t Halt Janssen’s Promo Comparing Their Psoriasis Drugs
Novartis Can’t Halt Janssen’s Promo Comparing Their Psoriasis Drugs
$131.00
A US district court judge recently denied a request from Novartis for a temporary restraining order against Janssen. Novartis was railing against Janssen’s promotional claims that Novartis’ IL-17A inhibitor Cosentyx (secukinumab) compares unfavorably to Janssen’s IL-23 inhibitor Tremfya (guselkumab) in safety tests. Find out more here.
Publisher: Pinksheet
- Description
Novartis was dealt a blow by a US District Court, which ruled that the company could not be granted a temporary restraining order against Janssen to stop the distribution of Janssen promotional materials that unfavorably compare the safety of a Novartis psoriasis drug, IL-17A inhibitor Cosentyx (secukinumab), to Janssen’s IL-23 inhibitor Tremfya (guselkumab). Find out more about the legal maneuverings behind this industry dispute and what they mean for both companies, in this insightful synopsis from the experts at Pink Sheet.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Multiple Myeloma Pricing, Reimbursement, and Access 
Sign up to the